BR112022018647A2 - Métodos para dose de iniciação de tratamentos com aripipazol - Google Patents
Métodos para dose de iniciação de tratamentos com aripipazolInfo
- Publication number
- BR112022018647A2 BR112022018647A2 BR112022018647A BR112022018647A BR112022018647A2 BR 112022018647 A2 BR112022018647 A2 BR 112022018647A2 BR 112022018647 A BR112022018647 A BR 112022018647A BR 112022018647 A BR112022018647 A BR 112022018647A BR 112022018647 A2 BR112022018647 A2 BR 112022018647A2
- Authority
- BR
- Brazil
- Prior art keywords
- aripipazole
- treatments
- dose
- methods
- aripiprazole
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 230000000977 initiatory effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 3
- 229960004372 aripiprazole Drugs 0.000 abstract 3
- 238000002347 injection Methods 0.000 abstract 2
- 239000007924 injection Substances 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
MÉTODOS PARA DOSE DE INICIAÇÃO DE TRATAMENTOS COM ARIPIPAZOL. A presente invenção refere-se a um método de iniciação de dose para um tratamento de aripiprazol para um paciente com necessidade do mesmo; é administrado para o paciente duas injeções separadas de 100 a 500 mg de uma formulação de depósito de aripiprazol intramuscular (IM), em locais de injeção glútea e/ou deltoide separados, e uma dose única de aripiprazol oral. A administração ocorre em um primeiro dia do tratamento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003544P | 2020-04-01 | 2020-04-01 | |
| PCT/JP2021/014194 WO2021201239A1 (en) | 2020-04-01 | 2021-04-01 | Methods for dose initiation of aripiprazole treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022018647A2 true BR112022018647A2 (pt) | 2022-11-08 |
Family
ID=75581573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018721A BR112022018721A2 (pt) | 2020-04-01 | 2021-04-01 | Métodos de administração de uma preparação injetável de aripiprazol |
| BR112022018647A BR112022018647A2 (pt) | 2020-04-01 | 2021-04-01 | Métodos para dose de iniciação de tratamentos com aripipazol |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022018721A BR112022018721A2 (pt) | 2020-04-01 | 2021-04-01 | Métodos de administração de uma preparação injetável de aripiprazol |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20220160621A1 (pt) |
| EP (2) | EP3941470A1 (pt) |
| JP (2) | JP2023519425A (pt) |
| KR (2) | KR20220161402A (pt) |
| CN (2) | CN115397420A (pt) |
| AU (2) | AU2021245713A1 (pt) |
| BR (2) | BR112022018721A2 (pt) |
| CA (3) | CA3163321C (pt) |
| MX (2) | MX2022012354A (pt) |
| TW (2) | TW202200141A (pt) |
| WO (2) | WO2021201239A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| ES2315721T5 (es) | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento |
| JOP20200109A1 (ar) * | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| US10525057B2 (en) | 2013-09-24 | 2020-01-07 | Otsuka Pharmaceutical Co., Ltd. | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
-
2021
- 2021-04-01 TW TW110112185A patent/TW202200141A/zh unknown
- 2021-04-01 CN CN202180025911.8A patent/CN115397420A/zh active Pending
- 2021-04-01 JP JP2022559751A patent/JP2023519425A/ja active Pending
- 2021-04-01 MX MX2022012354A patent/MX2022012354A/es unknown
- 2021-04-01 CN CN202180026022.3A patent/CN115379842A/zh active Pending
- 2021-04-01 BR BR112022018721A patent/BR112022018721A2/pt unknown
- 2021-04-01 CA CA3163321A patent/CA3163321C/en active Active
- 2021-04-01 MX MX2022012353A patent/MX2022012353A/es unknown
- 2021-04-01 KR KR1020227037400A patent/KR20220161402A/ko unknown
- 2021-04-01 CA CA3212191A patent/CA3212191A1/en active Pending
- 2021-04-01 CA CA3136727A patent/CA3136727A1/en active Pending
- 2021-04-01 EP EP21720011.2A patent/EP3941470A1/en active Pending
- 2021-04-01 BR BR112022018647A patent/BR112022018647A2/pt unknown
- 2021-04-01 WO PCT/JP2021/014194 patent/WO2021201239A1/en unknown
- 2021-04-01 US US17/594,292 patent/US20220160621A1/en active Pending
- 2021-04-01 US US17/907,583 patent/US20230129919A1/en active Pending
- 2021-04-01 TW TW110112186A patent/TW202200142A/zh unknown
- 2021-04-01 AU AU2021245713A patent/AU2021245713A1/en active Pending
- 2021-04-01 AU AU2021248212A patent/AU2021248212A1/en active Pending
- 2021-04-01 EP EP21720012.0A patent/EP4125903A1/en active Pending
- 2021-04-01 WO PCT/JP2021/014192 patent/WO2021201238A1/en active Application Filing
- 2021-04-01 KR KR1020227037401A patent/KR20220161403A/ko not_active Application Discontinuation
- 2021-04-01 JP JP2022559750A patent/JP2023520004A/ja active Pending
-
2023
- 2023-03-15 US US18/184,135 patent/US20230225962A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021245713A1 (en) | 2022-12-01 |
| US20230225962A1 (en) | 2023-07-20 |
| EP4125903A1 (en) | 2023-02-08 |
| MX2022012353A (es) | 2022-10-31 |
| WO2021201239A1 (en) | 2021-10-07 |
| CA3163321A1 (en) | 2021-10-07 |
| CN115397420A (zh) | 2022-11-25 |
| US20220160621A1 (en) | 2022-05-26 |
| JP2023520004A (ja) | 2023-05-15 |
| CA3163321C (en) | 2023-12-19 |
| JP2023519425A (ja) | 2023-05-10 |
| KR20220161402A (ko) | 2022-12-06 |
| MX2022012354A (es) | 2022-10-31 |
| BR112022018721A2 (pt) | 2022-11-01 |
| KR20220161403A (ko) | 2022-12-06 |
| TW202200142A (zh) | 2022-01-01 |
| AU2021248212A1 (en) | 2022-12-01 |
| CA3212191A1 (en) | 2021-10-07 |
| CA3136727A1 (en) | 2021-10-07 |
| WO2021201238A1 (en) | 2021-10-07 |
| US20230129919A1 (en) | 2023-04-27 |
| EP3941470A1 (en) | 2022-01-26 |
| CN115379842A (zh) | 2022-11-22 |
| TW202200141A (zh) | 2022-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Low-dose naltrexone for chronic pain: update and systemic review | |
| JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
| Donovan | Successful treatment of corticosteroid-resistant ophiasis-type alopecia areata (AA) with platelet-rich plasma (PRP) | |
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| NO333189B1 (no) | Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer. | |
| BR112018000051A2 (pt) | formulações para tratar síndrome de hunter e uso desta | |
| Morgante et al. | Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson’s disease: a follow-up of two years | |
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| Emir et al. | Tramadol Versus Low Dose Tramadol‐paracetamol for Patient Controlled Analgesia During Spinal Vertebral Surgery | |
| Zhou et al. | Combination of dexamethasone and tropisetron before thyroidectomy to alleviate postoperative nausea, vomiting, and pain: randomized controlled trial | |
| Ziemssen et al. | QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients | |
| MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| Finsterer et al. | Small fiber neuropathy | |
| Ozgul et al. | Effect of alkalinisation of lignocaine for propofol injection pain: a prospective, randomised, double-blind study | |
| BR112022018647A2 (pt) | Métodos para dose de iniciação de tratamentos com aripipazol | |
| BR112020013750A8 (pt) | Dispensação intranasal de olanzapina por dispositivo olfativo de precisão | |
| BR112021016913A2 (pt) | Método para tratar doenças relacionadas a tnfa | |
| Karlo et al. | Priming effects of propofol during induction of anesthesia | |
| Özdemir et al. | The effect of steroid injection by Novel method in carpal tunnel syndrome on pain severity and electrophysiological findings. | |
| BR112022004535A2 (pt) | Formulações de entrega de fármaco | |
| BR112022003687A2 (pt) | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina | |
| Modestin et al. | Haloperidol in Acute Schizophrenic Inpatients A Double-blind Comparison of Two Dosage Regimens | |
| Karadaş et al. | Comparison of single and repeated blockade of the greater occipital nerve in migraine treatment |